Claims

1. The use of a compound that is seladelpar or a salt thereof in the manufacture of an oral medicament for treating an intrahepatic cholestatic disease at a dose of 5 mg/day or 10 mg/day, when the dose is calculated as seladelpar.

2. The use of claim 1 where the compound is seladelpar L-lysine dihydrate.

3. The use of claim 1 or 2 where the dose of the compound is 5 mg/day.

4. The use of claim 1 or 2 where the dose of the compound is10 mg/day.

5. The use of any one of claims 1 to 4 where the compound is administered once/day.

6. The use of any one of claims 1 to 5 where the intrahepatic cholestatic disease is primary biliary cirrhosis, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis, or Alagille syndrome.

7. The use of claim 6 where the intrahepatic cholestatic disease is primary biliary cholangitis.

8. The use of claim 6 where the intrahepatic cholestatic disease is primary sclerosing cholangitis.

9. The use of claim 6 where the intrahepatic cholestatic disease is progressive familial intrahepatic cholestasis.

10. The use of claim 6 where the intrahepatic cholestatic disease is Alagille syndrome.

11. An oral pharmaceutical composition comprising a compound that is seladelpar or a salt thereof, where the amount of the compound is equivalent to 5 mg or 10 mg of seladelpar.

12. The oral pharmaceutical composition of claim 11 where the compound is seladelpar L-lysine dihydrate.

13. The oral pharmaceutical composition of claim 11 or 12 where the amount of the compound is equivalent to 5 mg of seladelpar.

14. The oral pharmaceutical composition of claim 11 or 12 where the amount of the compound is equivalent to 10 mg of seladelpar.

15. The oral pharmaceutical composition of any one of claims 11 to 14 that is a tablet or a capsule.